Expression and significance of 25-hydroxy vitamin D in rheumatic disease patients and the risk be-tween it and cardiovascular disease

Abstract

Objective To explore the expression and significance of 25-hydroxy vitamin D [25(OH)D] in rheumatic disease patients, and its association with the risk of cardiovascular disease(CVD). Methods The level of 25(OH)D, bone mineral density (BMD) test and clinical indicators of 134 rheumatic disease cases were analyzed retrospectively. T test was used for statistical analysis. Results Patients who were combined with CVD and rheumatic disease, the level of 25-hydroxy vitamin D was (13±8) ng/ml, who were without CVD the level was (14±8) ng/ml. There was no significant difference between two groups(t=0.638, P>0.05). But patients who were complicated with CVD and rheumatic diseases, their TC, TG, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein (Apo) A, ApoB and lipoprotein levels were higher than patients who were without CVDs (t=3.314, 3.397, 3.092, 2.159, 3.621, 2.011, 2.066, both P<0.05) , and their BMD was lower than patients who were without CVDs (t=-16.131, P<0.05). Conclusion To a certain extent, serum 25(OH)D levels of patients with rheumatic diseases is associated with CVD. Key words: Rheumatic diseases; Cardiovascular diseases; Vitamin D; Bone density; 25-hydroxy vitamin D